Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

With the respite in U.S. tariffs on key countries, investors could turn their attention to earnings. But Alphabet earnings failed to lift the mood.

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

French oil major TotalEnergies on Wednesday reported a sharp drop in full-year earnings, against a backdrop of lower crude ...

Wegovy maker Novo Nordisk has today forecast sales would grow at a slower rate this year although the outlook was roughly in ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen ...

A solid economy and still-too-high inflation argue for holding interest rates steady until more progress is made in slowing price growth, Federal Reserve Vice Chair Philip Jefferson said on Tuesday ...

The Japanese automakers had announced a plan to combine in December. The tech giant's fast-growing cloud-computing business decelerated last quarter. Shares were off more than 7% after hours.